中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway

文献类型:期刊论文

作者Li, YH; Chen, ZX; Lu, ZG; Yang, QH; Liu, LY; Jiang, ZT; Zhang, LQ; Zhang, X; Qing, H; Li, YanHui
刊名THERANOSTICS
出版日期2018
卷号8期号:19页码:5469
ISSN号1838-7640
关键词Parkinson's Disease Blood-brain-barrier Dopaminergic Neurons Cocaine Binding-site Egcg Alpha-synuclein Nanoparticles Dopamine Transporter Alpha-synclein Aggregation Laminin Receptor Tea Polyphenol Potential Inhibitors Alzheimers-disease Mazindol Analogs Delivery
DOI10.7150/thno.28295
文献子类Article
英文摘要

alpha-synclein (aS) aggregation is a representative molecular feature of the pathogenesis of Parkinson's disease (PD). Epigallocatechin gallate (EGCG) can prevent alpha S aggregation in vitro. However, the in vivo effects of PD treatment are poor due to the obstacles of EGCG accumulation in dopaminergic neurons, such as the blood brain barrier and high binding affinities between EGCG and membrane proteins. Therefore, the key to PD treatment lies in visual examination of EGCG accumulation in dopaminergic neurons. Methods: DSPE-PEG-B6, DSPE-PEG-MA, DSPE-PEG-phenylboronic acid, and superparamagnetic iron oxide nanocubes were self-assembled into tracing nanoparticles (NPs). EGCG was then conjugated on the surface of the NPs through the formation of boronate ester bonds to form a "cell-addictive" dual-target traceable nanodrug (B6ME-NPs). B6ME-NPs were then used for PD treatment via intravenous injection. Results: After treatment with B6ME-NPs, the PD-like characteristics was alleviated significantly. First, the amount of EGCG accumulation in PD lesions was markedly enhanced and traced via magnetic resonance imaging. Further, alpha S aggregation was greatly inhibited. Finally, the dopaminergic neurons were considerably increased. Conclusion: Due to their low price, simple preparation, safety, and excellent therapeutic effect on PD, B6ME-NPs are expected to have potential application in PD treatment.

WOS记录号WOS:000450037900018
资助机构Beijing Municipal Science & Technology Commission [Z161100002616015] ; National Natural Science Foundation of China [81671268, 81701260] ; Brain cognition and brain medicine of Beijing Municipal Science & Technology Commission [Z161100002616020] ; National High Technology Research and Development Program [2016YFA0200303] ; Beijing Natural Science Foundation [L172046]
源URL[http://ir.ipe.ac.cn/handle/122111/26823]  
专题中国科学院过程工程研究所
推荐引用方式
GB/T 7714
Li, YH,Chen, ZX,Lu, ZG,et al. Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway[J]. THERANOSTICS,2018,8(19):5469.
APA Li, YH.,Chen, ZX.,Lu, ZG.,Yang, QH.,Liu, LY.,...&Qing, Hong.(2018).Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway.THERANOSTICS,8(19),5469.
MLA Li, YH,et al."Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway".THERANOSTICS 8.19(2018):5469.

入库方式: OAI收割

来源:过程工程研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。